Core Viewpoint - Sanofi Pharmaceutical (01530.HK) has successfully completed a placement agreement, issuing a total of 105,169,500 shares at a price of HKD 29.62 per share, representing approximately 4.14% of the enlarged issued share capital [1] Group 1: Placement Details - The placement was completed on December 9, 2025, with shares allocated to no fewer than six subscribers [1] - The net proceeds from the placement, after deducting commissions and related expenses, amount to approximately HKD 3.087 billion [2] Group 2: Use of Proceeds - Approximately 80% or HKD 2,469.47 million of the net proceeds will be allocated for research and development expenses, which include: - Advancing clinical studies for innovative drugs in China and the U.S. to accelerate pipeline progress, including but not limited to drugs 705 (PD1/HER2), 706 (PD1/PDL1), 008 (B7H3/IL15), 59 (MUC17/CD3/CD28), 626 (BDCA2), and 627 (TL1A) [2] - Supporting the expansion of indications for commercialized drugs or clinical trials outside of China to enhance product value and market coverage, including but not limited to TPO and EPO [2] - Building global infrastructure and supporting facilities [2] - Approximately 20% or HKD 617.37 million will be used for working capital and other general corporate purposes to support the group's ongoing operations and strategic plans [2]

Group 1 - The core point of the article is that Sangfor Technologies (01530.HK) has entered into a placement agreement with Morgan Stanley to issue approximately 105 million shares at a price of HKD 29.62 per share, representing about 4.32% of the total issued shares as of the announcement date [1] - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion [2] Group 2 - The company plans to use approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting the expansion of indications for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]

配售事项的估计所得款项总额及所得款项净额将分别约为31.15亿港元及30.87亿港元。公司拟按以下方 式使用配售事项所得款项净额：(i)约80%用于研发相关开支，包括：(a)推进处于研发阶段的在研创新药 在中国及美国的临床研究，以加快管线进度，包括但不限于705(PD1/HER2)、706(PD1/PDL1)、 008(B7H3/IL15)、59(MUC17/CD3/CD28)、626(BDCA2)及627(TL1A)，(b)支持已商业化药物的适应症扩 展或在中国境外的临床试验，以进一步提升产品价值及扩大市场覆盖范围，包括但不限于特比澳 (TPO)、益比奥(EPO)，(c)建设全球基础设施及配套设施；及(ii)约20%用作营运资金及其他一般公司用 途，以支持集团的持续营运及战略计划。 来源：格隆汇APP 格隆汇12月2日丨三生制药(01530.HK)发布公告，2025年12月2日(交易时间前)，公司与独家配售代理(即 摩根士丹利)订立配售协议，据此，公司已有条件同意透过独家配售代理按每股配售股份29.62港元的价 格向不少于六名承配人配售合共约1.05亿股配售股份。配售股份占本公告日期已发行股份总数约 4.3 ...

Group 1 - Company announced a placement agreement with an exclusive placement agent to issue 105 million shares at a price of HKD 29.62 per share, which represents a discount of 6.50% compared to the closing price of HKD 31.68 on the trading day prior to the agreement [1] - The placement shares will account for approximately 4.14% of the total issued shares after the placement, assuming no changes in the company's issued share capital from the announcement date until completion [1] Group 2 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion after deducting placement commissions and other related expenses [2] - Approximately 80% of the net proceeds will be used for research and development, including advancing clinical studies for innovative drugs in China and the US, and supporting the expansion of indications for commercialized drugs [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]